NHS patients with a life-threatening heart condition are set to benefit from a medicine which can significantly reduce the risk of hospitalisation and death. The drug, tafamidis, is the first approved treatment for a cohort of patients in England with a rare heart condition known as transthyretin amyloidosis cardiomyopathy, where clumps of protein build up in the heart, often resulting in heart failure and potentially proving fatal.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.
Networks can be open to all or available only to a closed group defined by the administrator.
Join or create a network here.
